Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications
ABSTRACT Clinical trials of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutics often include virological secondary endpoints to compare viral clearance and viral load reduction between treatment and placebo arms. This is typically achieved using quantitative reverse-transcript...
Saved in:
Main Authors: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
American Society for Microbiology
2024-11-01
|
Series: | mSphere |
Subjects: | |
Online Access: | https://journals.asm.org/doi/10.1128/msphere.00304-24 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1846160997125980160 |
---|---|
author | Dominic Wooding Kate Buist Alessandra Romero-Ramirez Helen Savage Rachel Watkins Daisy Bengey Caitlin Greenland-Bews Caitlin R. Thompson Nadia Kontogianni Richard Body Gail Hayward Rachel L. Byrne Susan Gould Christopher Myerscough Barry Atkinson Victoria Shaw Bill Greenhalf Emily Adams Ana Cubas-Atienzar Saye Khoo Tom Fletcher Thomas Edwards |
author_facet | Dominic Wooding Kate Buist Alessandra Romero-Ramirez Helen Savage Rachel Watkins Daisy Bengey Caitlin Greenland-Bews Caitlin R. Thompson Nadia Kontogianni Richard Body Gail Hayward Rachel L. Byrne Susan Gould Christopher Myerscough Barry Atkinson Victoria Shaw Bill Greenhalf Emily Adams Ana Cubas-Atienzar Saye Khoo Tom Fletcher Thomas Edwards |
author_sort | Dominic Wooding |
collection | DOAJ |
description | ABSTRACT Clinical trials of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutics often include virological secondary endpoints to compare viral clearance and viral load reduction between treatment and placebo arms. This is typically achieved using quantitative reverse-transcriptase PCR (RT-qPCR), which cannot differentiate replicant competent virus from non-viable virus or free RNA, limiting its utility as an endpoint. Culture-based methods for SARS-CoV-2 exist; however, these are often insensitive and poorly standardized for use as clinical trial endpoints. We report optimization of a culture-based approach evaluating three cell lines, three detection methods, and key culture parameters. We show that Vero-angiotensin-converting enzyme 2-transmembrane serine protease 2 cells in combination with RT-qPCR of culture supernatants from the first passage provides the greatest overall detection of Delta viral replication (22 of 32, 68.8%), being able to identify viable virus in 83.3% (20 of 24) of clinical samples with initial Ct values of <30. Likewise, we demonstrate that RT-qPCR using culture supernatants from the first passage of Vero human signaling lymphocytic activation molecule cells provides the highest overall detection of Omicron viral replication (9 of 31, 29%), detecting live virus in 39.1% (9 of 23) of clinical samples with initial Ct values of <25. This assessment demonstrates that combining RT-qPCR with virological endpoint analysis has utility in clinical trials of therapeutics for SARS-CoV-2; however, techniques may require optimization based on dominant circulating strain.IMPORTANCERT-qPCR is commonly used for virological endpoints during clinical trials for antiviral therapy to determine the quantity and presence of virus in a sample. However, RT-qPCR identifies viral RNA and cannot determine if viable virus is present. Existing culture-based techniques for SARS-CoV-2 are insensitive and not sufficiently standardized to be employed as clinical study endpoints. The use of a culture system to monitor replicating viruses could mitigate the possibility of molecular techniques identifying viral RNA from inactive or lysed viral particles. The methodology optimized in this study for detecting infectious viruses may have application as a secondary virological endpoint in clinical trials of therapeutics for SARS-CoV-2 in addition to numerous research processes. |
format | Article |
id | doaj-art-b9fee6f82ea04a7885599c6002c3fe27 |
institution | Kabale University |
issn | 2379-5042 |
language | English |
publishDate | 2024-11-01 |
publisher | American Society for Microbiology |
record_format | Article |
series | mSphere |
spelling | doaj-art-b9fee6f82ea04a7885599c6002c3fe272024-11-21T14:00:48ZengAmerican Society for MicrobiologymSphere2379-50422024-11-0191110.1128/msphere.00304-24Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applicationsDominic Wooding0Kate Buist1Alessandra Romero-Ramirez2Helen Savage3Rachel Watkins4Daisy Bengey5Caitlin Greenland-Bews6Caitlin R. Thompson7Nadia Kontogianni8Richard Body9Gail Hayward10Rachel L. Byrne11Susan Gould12Christopher Myerscough13Barry Atkinson14Victoria Shaw15Bill Greenhalf16Emily Adams17Ana Cubas-Atienzar18Saye Khoo19Tom Fletcher20Thomas Edwards21Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomDepartment of Clinical Sciences, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomManchester University NHS Foundation Trust, Research and Innovation, Manchester, United KingdomNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United KingdomDepartment of Clinical Sciences, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomResearch and Evaluation, UK Health Security Agency, Porton Down, Salisbury, United KingdomUniversity of Liverpool, Liverpool, United KingdomUniversity of Liverpool, Liverpool, United KingdomCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomUniversity of Liverpool, Liverpool, United KingdomDepartment of Clinical Sciences, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomCentre for Drugs and Diagnostics, Liverpool School of Tropical Medicine and Hygiene, Liverpool, United KingdomABSTRACT Clinical trials of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) therapeutics often include virological secondary endpoints to compare viral clearance and viral load reduction between treatment and placebo arms. This is typically achieved using quantitative reverse-transcriptase PCR (RT-qPCR), which cannot differentiate replicant competent virus from non-viable virus or free RNA, limiting its utility as an endpoint. Culture-based methods for SARS-CoV-2 exist; however, these are often insensitive and poorly standardized for use as clinical trial endpoints. We report optimization of a culture-based approach evaluating three cell lines, three detection methods, and key culture parameters. We show that Vero-angiotensin-converting enzyme 2-transmembrane serine protease 2 cells in combination with RT-qPCR of culture supernatants from the first passage provides the greatest overall detection of Delta viral replication (22 of 32, 68.8%), being able to identify viable virus in 83.3% (20 of 24) of clinical samples with initial Ct values of <30. Likewise, we demonstrate that RT-qPCR using culture supernatants from the first passage of Vero human signaling lymphocytic activation molecule cells provides the highest overall detection of Omicron viral replication (9 of 31, 29%), detecting live virus in 39.1% (9 of 23) of clinical samples with initial Ct values of <25. This assessment demonstrates that combining RT-qPCR with virological endpoint analysis has utility in clinical trials of therapeutics for SARS-CoV-2; however, techniques may require optimization based on dominant circulating strain.IMPORTANCERT-qPCR is commonly used for virological endpoints during clinical trials for antiviral therapy to determine the quantity and presence of virus in a sample. However, RT-qPCR identifies viral RNA and cannot determine if viable virus is present. Existing culture-based techniques for SARS-CoV-2 are insensitive and not sufficiently standardized to be employed as clinical study endpoints. The use of a culture system to monitor replicating viruses could mitigate the possibility of molecular techniques identifying viral RNA from inactive or lysed viral particles. The methodology optimized in this study for detecting infectious viruses may have application as a secondary virological endpoint in clinical trials of therapeutics for SARS-CoV-2 in addition to numerous research processes.https://journals.asm.org/doi/10.1128/msphere.00304-24molecular diagnosticsclinical trialsCOVID-19 |
spellingShingle | Dominic Wooding Kate Buist Alessandra Romero-Ramirez Helen Savage Rachel Watkins Daisy Bengey Caitlin Greenland-Bews Caitlin R. Thompson Nadia Kontogianni Richard Body Gail Hayward Rachel L. Byrne Susan Gould Christopher Myerscough Barry Atkinson Victoria Shaw Bill Greenhalf Emily Adams Ana Cubas-Atienzar Saye Khoo Tom Fletcher Thomas Edwards Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications mSphere molecular diagnostics clinical trials COVID-19 |
title | Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications |
title_full | Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications |
title_fullStr | Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications |
title_full_unstemmed | Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications |
title_short | Optimization of SARS-CoV-2 culture from clinical samples for clinical trial applications |
title_sort | optimization of sars cov 2 culture from clinical samples for clinical trial applications |
topic | molecular diagnostics clinical trials COVID-19 |
url | https://journals.asm.org/doi/10.1128/msphere.00304-24 |
work_keys_str_mv | AT dominicwooding optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT katebuist optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT alessandraromeroramirez optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT helensavage optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT rachelwatkins optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT daisybengey optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT caitlingreenlandbews optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT caitlinrthompson optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT nadiakontogianni optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT richardbody optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT gailhayward optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT rachellbyrne optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT susangould optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT christophermyerscough optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT barryatkinson optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT victoriashaw optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT billgreenhalf optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT emilyadams optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT anacubasatienzar optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT sayekhoo optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT tomfletcher optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications AT thomasedwards optimizationofsarscov2culturefromclinicalsamplesforclinicaltrialapplications |